Physician profile
Ronald Daniel Emkey
NPI 1265592414
$140,754.10
in general payments reported to CMS, 2019-2025
30 companies · $6,462 in 2025
The $6,462 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $10K · 2021: $18K · 2022: $8,056 · 2023: $3,200 · 2024: $8,473 · 2025: $6,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $2,559 · Travel and Lodging: $1,991 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,569.00 |
| Food and Beverage | $2,559.40 |
| Travel and Lodging | $1,991.05 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $135,577.57 | 2019-2025 | Evenity, Prolia, Tavneos |
| Abbvie INC. | $2,233.15 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $406.20 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $350.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $338.22 | 2019-2024 | Benlysta |
| Genentech USA, INC. | $220.66 | 2019-2021 | |
| Pfizer INC. | $192.08 | 2019-2023 | |
| Janssen Biotech, INC. | $167.14 | 2019-2024 | Tremfya |
| Lilly USA, LLC | $155.26 | 2019-2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $130.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $126.65 | 2019 | |
| Aurinia Pharma U.S., INC. | $98.65 | 2023-2024 | Lupkynis |
| Genzyme Corporation | $82.57 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $75.61 | 2023-2024 | Purified Cortrophin Gel |
| Ucb, INC. | $73.96 | 2024 | Cimzia, Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medexus Pharma, INC. | $72.59 | 2019 | |
| Mallinckrodt Hospital Products INC. | $69.39 | 2022 | |
| Sobi, INC | $66.16 | 2019-2023 | |
| Radius Health, INC. | $58.67 | 2019 | |
| Depuy Synthes Sales INC. | $46.97 | 2019-2024 | Monovisc |
| Ultragenyx Pharmaceutical INC. | $45.29 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $42.63 | 2021-2024 | Saphnelo |
| Bioventus LLC | $36.28 | 2019-2022 | |
| Organon LLC | $23.48 | 2021 | |
| Celgene Corporation | $20.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.83 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $14.16 | 2024 | Arcalyst |
| Horizon Therapeutics Plc | $13.63 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Emkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.